Fundraising FoxIRX Therapeutics
New York, US · Delaware corporation
Find your way into IRX Therapeutics
Sign up to see every warm intro you have to IRX Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the IRX Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
JW
John W. Hadden IIExecutive
JH
Jeffrey HwangExecutive
CP
Curtis P. RobbExecutive
ZR
Zygmund RothExecutive
Board
JD
John D. HalpernBoard director
GP
George P. Denny IIIBoard director
DH
David H. DemingBoard director
FM
Ferid MuradBoard director
JT
John T. SpitznagelBoard director
LM
Lawrence M. WolfBoard director
Reported raises · per SEC filings
Form D private placements$97.3M disclosed across 5 rounds · 2014–2016
▶$33.2MraisedAug 2017 · 98 investors · BiotechnologyRule 506(b)
▶$33.2MraisedAug 2017 · 98 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark W. LeuchtenbergerExecutive Officer, Director
- John D. HalpernDirector
- Ferid MuradDirector
- Lawrence M. WolfDirector
- Edmund TruellDirector
- Charles R. CheringtonDirector
- Zygmund RothExecutive Officer
- David H. DemingDirector
- Monil ShahExecutive Officer
- Curtis P. RobbExecutive Officer
- George P. Denny IIIDirector
- Offering amount
- $33.2M
- Amount sold
- $33.2M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.4MraisedNov 2016 · 4 investors · BiotechnologyRule 506(b)
▶$6.4MraisedNov 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- Ferid MuradDirector
- Lawrence M. WolfDirector
- Charles R. CheringtonDirector
- John W. Hadden IIExecutive Officer, Director
- David H. DemingDirector
- John D. HalpernDirector
- Curtis P. RobbExecutive Officer
- Jeffrey HwangExecutive Officer
- Offering amount
- $8M
- Amount sold
- $6.4M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMay 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedMay 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Curtis P. RobbExecutive Officer
- Charles R. CheringtonDirector
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- John W. Hadden IIExecutive Officer, Director
- David H. DemingDirector
- Lawrence M. WolfDirector
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- Ferid MuradDirector
- Offering amount
- $15M
- Amount sold
- $2M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.6MraisedAug 2015 · 230 investors · BiotechnologyRule 506(b)
▶$40.6MraisedAug 2015 · 230 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John W. Hadden IIExecutive Officer, Director
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- Curtis P. RobbExecutive Officer
- David H. DemingDirector
- Zygmund RothExecutive Officer
- George P. Denny IIIDirector
- Ferid MuradDirector
- John T. SpitznagelDirector
- Lawrence M. WolfDirector
- Offering amount
- $40.6M
- Amount sold
- $40.6M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.1MraisedMar 2014 · 104 investors · BiotechnologyRule 506(b)
▶$15.1MraisedMar 2014 · 104 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ferid MuradDirector
- Lawrence M. WolfDirector
- George P. Denny IIIDirector
- David H. DemingDirector
- Zygmund RothExecutive Officer
- Curtis P. RobbExecutive Officer
- John W. Hadden IIExecutive Officer, Director
- John D. HalpernDirector
- Jeffrey HwangExecutive Officer
- John T. SpitznagelDirector
- Offering amount
- $18M
- Amount sold
- $15.1M
- First sale
- Feb 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has IRX Therapeutics raised?
- IRX Therapeutics has disclosed $97.3M raised across 5 rounds.
- Where is IRX Therapeutics headquartered?
- IRX Therapeutics is headquartered in New York, US.